Summit Therapeutics (SMMT) — insider trading
Health Care · NASDAQ
Summit Therapeutics (SMMT) has 15 reported SEC Form 4 insider transactions in our data, including 6 open-market purchases among the most recent 15 (latest 2026-06-12).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-12 | DUGGAN ROBERT W | Director, Officer (Co-Chief Executive Officer), 10% owner | Open-market purchase | 3,810,000 | $13.12 | $49.99M | Form 4 |
| 2026-06-12 | Zanganeh Mahkam | Director, Officer (Co-Chief Executive Officer), 10% owner | Open-market purchase | 3,810,000 | $13.12 | $49.99M | Form 4 |
| 2026-06-04 | Soni Manmeet Singh | Director, Officer (COO and CFO) | Open-market purchase | 25,000 | $14.43 | $360.8K | Form 4 |
| 2026-06-04 | Soni Manmeet Singh | Director, Officer (COO and CFO) | Open-market purchase | 25,000 | $14.46 | $361.5K | Form 4 |
| 2026-06-04 | Zanganeh Mahkam | Director, Officer (Co-Chief Executive Officer), 10% owner | Open-market purchase | 100,000 | $14.60 | $1.46M | Form 4 |
| 2026-06-04 | DUGGAN ROBERT W | Director, Officer (Co-Chief Executive Officer), 10% owner | Open-market purchase | 100,000 | $14.60 | $1.46M | Form 4 |
| 2026-01-08 | Anand Bhaskar | Officer (Chief Accounting Officer) | Grant / award / vesting (derivative) | 30,000 | — | — | Form 4 |
| 2026-01-02 | Ronaghi Mostafa | Director | Grant / award / vesting (derivative) | 35,000 | — | — | Form 4 |
| 2026-01-02 | Huber Jeff | Director | Grant / award / vesting (derivative) | 9,885 | $8.76 | $86.6K | Form 4 |
| 2026-01-02 | Huber Jeff | Director | Grant / award / vesting (derivative) | 35,000 | — | — | Form 4 |
| 2026-01-02 | Xia Yu | Director | Grant / award / vesting (derivative) | 35,000 | — | — | Form 4 |
| 2026-01-02 | Booth Robert F. | Director | Grant / award / vesting (derivative) | 7,180 | $8.76 | $62.9K | Form 4 |
| 2026-01-02 | Booth Robert F. | Director | Grant / award / vesting (derivative) | 35,000 | — | — | Form 4 |
| 2026-01-02 | DUGGAN ROBERT W | Director, Officer (Co-Chief Executive Officer), 10% owner | Grant / award / vesting (derivative) | 11,232 | $8.76 | $98.4K | Form 4 |
| 2026-01-02 | Zanganeh Mahkam | Director, Officer (Co-Chief Executive Officer), 10% owner | Grant / award / vesting (derivative) | 11,232 | $8.76 | $98.4K | Form 4 |
Ask the chat about SMMT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Summit Therapeutics (SMMT).
Last updated 2026-06-12 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.